News

A team of scientists have conducted preclinical trials of a novel drug nanocarrier, 3HM, that may offer a solution to breaking the blood-brain barrier in the treatment of brain cancers like glioblastoma multiforme.

A team of scientists from Virginia Tech Carilion Research Institute and clinicians from Carilion Clinic may have found a way to increase sensitivity to the front-line chemotherapeutic agent temozolomide (TMZ) in glioblastoma (GBM), even after resistance.

Patients receiving a combination of MEK inhibitor trametinib and BRAF inhibitor dabrafenib not only greatly improves long-term outcomes, but also lowers some adverse events associated with either standalone agent for patients with BRAF-mutated metastatic melanoma.

Where once limited treatment options existed for patients with CLL, medical oncologists now have a plethora of agents from which to choose, making disease management in CLL more effective with fewer toxicities.

The treatment paradigm for renal cell carcinoma (RCC) could undergo major changes in the future due to several novel therapies in the works for regulatory approval and checkpoint inhibitors, vaccines, recombinant T-cell receptors, and bi-specific T-cell engagers.

An FDA panel voted against approval of the immunotherapy MCNA as a treatment for patients with high-risk non-muscle invasive bladder cancer (NMIBC) following first-line bacillus Calmette-Guerin (BCG) therapy.

Several recent trials have shown that a combination of docetaxel in conjunction with androgen deprivation therapy (ADT) is optimal in treating oligometastatic prostate cancer.

Despite the small size of the pigeon brain, our Columba livia counterparts have performed just as well as humans in distinguishing between normal tissue and breast cancer tissue in a study performed by researchers at the University of Iowa and the University of California, Davis.

Andre Goy, MD, MS, chief, John Theurer Cancer Center's Division of Lymphoma, talks about the emerging novel therapies in diffuse large B-cell lymphoma (DLBCL).

Avelumab has been given breakthrough therapy designation by the FDA as a possible treatment for patients with metastatic Merkel cell carcinoma (MCC) following progression on at least one prior chemotherapy regimen

Select medical centers nationwide are now offering blue-light cystoscopy imaging to better detect papillary cancer of the bladder.

Bladder cancer may soon catch up to other areas of oncology in terms of an influx of immunotherapies, according to Thomas Powles, MD.

The PD-1 inhibitor nivolumab (Opdivo) has gained a priority review status from the FDA as a treatment for patients with advanced renal cell carcinoma (RCC) following prior antiangiogenic therapy.

The FDA has given accelerated approval to the CD38-targeted monoclonal antibody daratumumab as a monotherapy for patients with multiple myeloma following at least 3 prior therapies a full four months ahead of schedule.

A supplemental new drug application has been submitted to the FDA for ibrutinib in conjunction with bendamustine and rituximab. The combination would treat patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Vitamin C, often used to fight colds and other pathogens, may also be a powerful weapon against colorectal cancer (CRC), according to a study published in Science.

A number of colorectal cancer care advocacy groups and the American Cancer of Radiology are lobbying Congress to pass the CT Colonography Screening for Colorectal Cancer Act, an initiative that could lower costs and increase screening rates.

From its approval in May 2013 to recently being considered as a combination treatment with other drugs, radium-223 dichloride shows great potential in positively impacting treatment for mCRPC, according to Dr. Michael Morris.

Dead bacteria cells and bacteria excretions from Clostridium sporogenes have successfully been used to kill colorectcal cancer cells in a preclinical study performed by researchers at the Nanyang Technological University in Singapore.

The FDA has given osimertinib (Tagrisso, AZD9291) an accelerated approval for treatment of patients with advanced EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) following progression on a prior EGFR TKI.

"We should be doing this, because we understand the disease, we see these patients, and we're not just surgeons, Dr. Adam Kibel said. "We were giving them medications to control their BPH before we diagnosed them with cancer."

With novel treatments such as abiraterone acetate (Zytiga) and enzalutamide (Xtandi) emerging and financial challenges of diminished reimbursement faced by urology practices mounting, urology groups are beginning to offer in-office dispensing to their metastatic castration-resistant prostate cancer (mCRPC) patients.

Patients with ovarian cancer who have high-to-medium expression of folate receptor alpha responded well overall to mirvetuximab soravtansine.

The FDA has approved a combination of vemurafenib (Zelboraf) and cobimetinib (Cotellic) to treat patients with metastatic or unresectable BRAF V600E/K mutation-positive melanoma.

Findings from a recent study suggest that women whose breast cancers have a higher proportion of blood vessels may benefit more from neoadjuvant treatment with bevacizumab than women whose tumors have a lower density of blood vessels.

Investigators of a new phase II study reported that favorable-risk oropharyngeal squamous cell carcinoma testing positive for human papillomavirus or p16 can be treated successfully using substantially decreased chemoradiotherapy doses.

The storied history of Trabectedin, a treatment for metastatic liposarcoma or leiomyosarcoma, all starts in the shallow, warm waters of the ocean.

Gregory J. Riely, MD, PhD, vice chair of the Clinical Trials Office in the Department of Medicine, Memorial Sloan Kettering Cancer Center, talks about non-small cell lung cancer (NSCLC) MET exon 14 mutations and their response to drugs like cabozantinib and crizotinib.

From just chemotherapy to molecular and immune focused therapies, the landscape of non-small cell lung cancer (NSCLC) has drastically changed over the course of the last 10 years according to Heather Wakelee, MD.

Mutations in MYD88 and CXCR4 can effectively be used to tailor treatment for patients with Waldenstrom's macroglobulinemia (WM), according to one medical professional.